NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
TRIJARDY XR (empagliflozin, linagliptin, metformin hydrochloride) by Boehringer Ingelheim is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIJARDY XR is a fixed-dose combination tablet containing empagliflozin (SGLT2 inhibitor), linagliptin (DPP-4 inhibitor), and metformin hydrochloride (biguanide) in extended-release formulation, approved by the FDA on January 27, 2020. It is indicated for the treatment of type 2 diabetes mellitus in patients inadequately controlled on diet and exercise alone or as an adjunct to other antidiabetic agents. The product combines three complementary mechanisms of action to improve glycemic control through enhanced urinary glucose excretion, incretin preservation, and hepatic glucose suppression. TRIJARDY XR represents a triple-combination approach designed to address multiple pathophysiologic defects in type 2 diabetes management.
$0.1BPart D
11.6 years to LOEMechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIJARDY XR creates opportunities across multiple commercial roles including brand management, field sales representatives targeting endocrinologists and primary care physicians, and medical science liaisons positioned to engage healthcare providers on combination therapy advantages. Success in this role requires deep understanding of type 2 diabetes treatment algorithms, cardiovascular and renal benefit differentiation, and medication adherence advantages of fixed-dose combinations. Currently zero open positions are linked to this product in available job tracking systems, suggesting stable staffing levels for this established product in peak lifecycle stage.
Company
Worked on TRIJARDY XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.